Download - The role of commercial enterprises in health
![Page 1: The role of commercial enterprises in health](https://reader035.vdocument.in/reader035/viewer/2022081515/56814a38550346895db75451/html5/thumbnails/1.jpg)
The role of commercial enterprises in health
Dr. Petra Laux, GSK Brussels
September 2001
![Page 2: The role of commercial enterprises in health](https://reader035.vdocument.in/reader035/viewer/2022081515/56814a38550346895db75451/html5/thumbnails/2.jpg)
Global Presence of GlaxoSmithKline
•GSK GSK is one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market.
•GSK R&D GSK R&D has 24 sites in 7 countries and the budget is about £2.4bn/$4bn.
•Global Manufacturing and SupplyGlobal Manufacturing and Supply: GSK has 108 manufacturing sites in 41 countries
•GSK has over 100,000 employees worldwide
![Page 3: The role of commercial enterprises in health](https://reader035.vdocument.in/reader035/viewer/2022081515/56814a38550346895db75451/html5/thumbnails/3.jpg)
OutlineTo bear witness of the views of
various GSK senior executives on
the challenge of improving healthcare
who can help industry’s role and principles
Peter
![Page 4: The role of commercial enterprises in health](https://reader035.vdocument.in/reader035/viewer/2022081515/56814a38550346895db75451/html5/thumbnails/4.jpg)
Our mission“Our global quest is to
improve the quality of human life by enabling people to do more, feel better and live longer”
But: Many people in developing countries do not have access to basic health care services, including safe and effective medicines
![Page 5: The role of commercial enterprises in health](https://reader035.vdocument.in/reader035/viewer/2022081515/56814a38550346895db75451/html5/thumbnails/5.jpg)
Our commitment addresses three critical areas:
1. Investment in research and development to the developing world
2. Sustainable preferential pricing
3. Community activities that promote effective healthcare
![Page 6: The role of commercial enterprises in health](https://reader035.vdocument.in/reader035/viewer/2022081515/56814a38550346895db75451/html5/thumbnails/6.jpg)
Sustainable Preferential Pricing
Current scheme: all Least Developed Countries and all
countries in Sub-Saharan Africa Governments, international agencies,
NGOs, charities and international purchase funds; employers
all HIV, all anti-malarials pilot for anti-infectives, de-worming
agents and anti-diarrhoeals
![Page 7: The role of commercial enterprises in health](https://reader035.vdocument.in/reader035/viewer/2022081515/56814a38550346895db75451/html5/thumbnails/7.jpg)
Sustainability of preferential pricing
no prices below costs
no benchmarking of prices to developed world
no product diversion/parallel trade of preferential priced products
partnership
full IP Protection
![Page 8: The role of commercial enterprises in health](https://reader035.vdocument.in/reader035/viewer/2022081515/56814a38550346895db75451/html5/thumbnails/8.jpg)
Access to medicines
is a complex and multifaceted issue, rooted in poverty
– limited access to food and clean water
– shortage of hospitals and clinics to administer medicines
– poor distribution networks
– high levels of illiteracy
– low numbers of trained healthcare workers
– lack of political will: health as a priority
![Page 9: The role of commercial enterprises in health](https://reader035.vdocument.in/reader035/viewer/2022081515/56814a38550346895db75451/html5/thumbnails/9.jpg)
A rich R & D pipeline for the developing world: 20 active projects
hepatitis E vaccine, meningitis A and C combination vaccine, new diphtheria, tetanus, pertussis, hepatitis B vaccine, Malaria LAPDAP, for resistant infections, LAPDAP + artesunate (CDA), for acute, uncomplicated malaria; Malarone in the treatment of infants, children; Malarone in complicated, severe malaria; tafenoquine for the prevention of malaria; a tuberculosis vaccine (in collaboration with Corixa); tuberculosis chemotherapy (in partnership with the National Institutes of Health and St. Jude’s Children’s Research Hospital); Oxibendazole (for women of child-bearing age); sitamaquine for visceral leishmaniasis; a new combination product and a novel protease inhibitor for HIV/AIDS
Photos (taken out to reduce data)
![Page 10: The role of commercial enterprises in health](https://reader035.vdocument.in/reader035/viewer/2022081515/56814a38550346895db75451/html5/thumbnails/10.jpg)
What about Intellectual Property?
Patent protection stimulates and fundamentally underpins continued research and development
Focus on IP and the TRIPs agreement in the access debate is misleading and counter-productive:
95% of EDL medicines protected, 30% people no access
countries without IP have no better access: India only 15% of ARVs are patent protected TRIPS not implemented yet in many countries (50%) preferential priced products are available
![Page 11: The role of commercial enterprises in health](https://reader035.vdocument.in/reader035/viewer/2022081515/56814a38550346895db75451/html5/thumbnails/11.jpg)
TRIPS and Doha
TRIPS contains inbuilt flexibilities to safeguard public health, eg Compulsory licensing, parallel trade
no reopening necessary
any clarification in line with existing agreement
![Page 12: The role of commercial enterprises in health](https://reader035.vdocument.in/reader035/viewer/2022081515/56814a38550346895db75451/html5/thumbnails/12.jpg)
Shared Responsibilities